Exploratory Trial of Lurbinectedin and Radiotherapy in SCLC Progression
An exploratory trial is assessing the safety of combining lurbinectedin with radiotherapy in patients with SCLC showing single-lesion progression.
Asset / Drug
Drug and asset intelligence for Lurbinectedin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.